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ABSTRACT 
Sustained release drug delivery system can be a major advance toward solving the problem concerning drugs have a 
short half-life are eliminated quickly from blood circulation require frequent dosing. To avoid this problem, oral 
sustained release formulations have been developed in an attempt to release the drug slowly into the g.i.t and 
maintain a constant drug concentration for long period of time. Purpose of review article is designing sustained 
release drug delivery system is to reduce the frequency of dosing, reduce the dose and provide uniform drug 
delivery. Present review article compile various formulation approaches for sustained release drug delivery system 
such as objectives of SRDDS, disadvantages of conventional dosage form, advantages, factors in designing of 
SRDDS, drug selection , polymers used, models and comparison of dissolution profile , characterization of sustained 
release tablets. 
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Introduction 
 
Probably the earliest work in the area of sustained 
drug delivery dosage forms can be traced to the 1938 
patent of Israel Lipowski. This work involved coated 
pallets for prolonged release of drug and was 
presumably forerunner to the development of the 
coated particle approach to sustained drug delivery 
that introduced in the early 1950s [1].The novel 
system of drug delivery offer a means of improving 
the therapeutic effectiveness of incorporated drugs by 
providing sustained, controlled delivery and / or 
targeting the drug to desired site. The goal of any 
drug delivery system is to provide a therapeutic 
amount of drug to the proper site in the body to 
achieve promptly and then maintain the desired drug 
concentration [2,3]. Sustained release systems 
include any drug delivery system that achieves slow 
release of drug over an extended period of time. If the 
system is successful in maintaining constant drug 
levels in the blood or target tissue, it is considered as 
a controlled-release system.  
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If it is unsuccessful at this but nevertheless extends 
the duration of action over that achieved by 
conventional delivery, it is considered as a prolonged 
release system. The oral route of administration for 
sustained release systems has received greater 
attention because of more flexibility in dosage form 
design[4].Sustained release delivery systems is 
subjected to several interrelated variables of 
considerable importance such as the type of delivery 
system, the disease being treated, the patient, the 
length of therapy and the properties of the drug. 
Sustain release system includes any drug delivery 
systems that achieves slow release of drug over an 
extended period of time. If the systems can provide 
some control, whether this is of temporal or spatial 
nature, or both, of drug release in the body, or in 
other words, the system is successful at maintaining 
constant drug levels in the target tissue or cells, it is 
considered a controlled-release system [5]. In recent 
years, in association with progress and innovation in 
the field of pharmaceutical technology, there has 
been an increasing effort to develop sustained release 
dosage forms for many drugs. The primary objective 
of this system is to ensure safety and to improve 
efficacy of the drugs as well as patient compliance. 
This is achieved by better control of plasma drug 
levels and less frequent dosing. Pharmacokinetic 
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theory suggests that the ultimate method for reducing 
the plasma maximum concentration (Cmax) to 
plasma minimum concentration (Cmin) ratio is to 
have zero- order absorption. Once steady state is 
achieved under these conditions, drug concentration 
in plasma is constant as long as absorption persists. 
Successful commercialization of an extended release 
formulation is usually challenging and involves 
consideration of many factors such as 
physiochemical properties of the drug, physiological 
factors, and manufacturing variables [6,7]. 
                  
 
Figure 1: Plasma drug concentration profiles for conventional tablet formulation, a sustained release 
formulation and a zero order controlled release formulation 
 
Objectives of oral sustained released dosage form  
• To maintain the concentration of drug at 
constant level for a desired period of time.  
• To reduce the frequency of doses 
administrated as compared to conventional 
dosage form  
• It should deliver active entity directly to site 
of action, minimizing or eliminating side 
effects. 
• This may necessitate delivery to specific 
receptors or to localization to cells or to 
specific areas of the body. 
• The safety margin of potent drugs can be 
increased. 
• Incidence of both local and systemic adverse 
side effects can be reduced in sensitive patient 
[8,9,10,11]. 
Disadvantages of conventional dosage forms 
 
• Poor patient compliance, increased chances of 
missing the dose of a drug with short half-life 
for which frequent administration is 
necessary. 
• A typical peak-valley plasma concentration 
time profile is obtained which makes 
attainment of steady-state condition difficult. 
• The unavoidable fluctuations of drug 
concentration may lead to under medication or 
over medication. 
• The fluctuations in drug levels may lead to 
precipitation of adverse effects especially of a 
drug with small Therapeutic Index whenever 
over medication occur [12,13]. 
 
Advantages of sustained release drug delivery 
system 
Clinical advantages  
 
• Patient compliance can be improved. 
• Reduction in fluctuation in steady levels and 
better control of disease condition and reduced 
intensity of local and systemic side effects. 
• Increased safety of margin of high potency of 
drugs. 
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• Maximum utilization of drug enabling 
reduction in total amount of dose. 
• Improve therapy cost 
• Shorter treatment period 
• Lower frequency of dosing [14]. 
Commercial / Industrial Advantages 
 
• Illustration of innovative /technological 
• Leadership 
• Product life-cycle extension 
• Product differentiation 
• Market expansion 
• Patent extension[15] 
Challenges to sustained release drug delivery 
 
1. Biocompatibility  
2. Cost of formulation, preparation and 
processing 
3. Fate of controlled release system if not 
biodegradable  
4. Fate of polymer additives, e.g., plasticizers, 
stabilizers, antioxidants, fillers etc [16]. 
 
Factors in the designing of sustained release drug 
delivery systems 
 
A. Biopharmaceutics characteristics of drug in 
the design of SRDDS 
 
• Molecular size and diffusivity  
Diffusivity depends on size & shape of the 
cavities of the membrane. The diffusion 
coefficient of intermediate molecular weight 
drug is 100-400 Daltons; through flexible 
polymer range is 10-6-10-9 cm2/sec. For 
drugs having molecular weight > 500 Daltons, 
the diffusion coefficient in many polymers are 
very less i.e. less than 10-12 cm2/sec. The 
examples of drugs which are difficult to 
control release rate of medicament from 
dosage form are proteins and peptides. 
• Partition coefficient (P (o/w)) 
Partition coefficient is defined as the fraction 
of drug in an oil phase to that of an adjacent 
aqueous phase. Drugs that passes though 
biological membrane, if partition co-efficient 
of drug influences shows very much 
bioavailability because lipophilic nature of 
biological membrane. Drugs that have lower 
partition coefficient are not suitable for oral 
CR drug delivery system and drugs that have 
higher partition coefficient are also not 
suitable for oral SR drug delivery system 
because they will not partition out of the lipid 
membrane once it gets in the membrane. 
• Drug pKa and ionization at physiological 
pH  
Drugs existing largely in ionized form are 
poor candidates for oral Sustained release 
drug delivery system. Absorption of the 
unionized drugs are well whereas permeation 
of ionized drug is negligible because the 
absorption rate of ionized drug is 3-4 times 
less than that of the unionized drug. The pKa 
range for acidic drug whose ionization is pH 
sensitive is around 3.0-7.5 and pKa range for 
basic drug whose ionization is pH sensitive is 
around 7.0-11.0 are ideal for optimum positive 
absorption. Drug shall be unionized at the site 
to an extent 0.1-5.0%. 
• Drug stability  
Drugs undergo both acid/base hydrolysis and 
enzymatic degradation when administered oral 
route. If the drug in the solid state the 
degradation will occur in reduced rate, for the 
drugs that are unstable in stomach that 
prolong delivery to the entire GI tract are 
beneficial. If drug is administered in extended 
release dosage form that are unstable in small 
intestine may demonstrate decreased 
bioavailability. This occurs due to the fact that 
a greater quantity of drug is delivered in small 
intestine and is being subjected to more 
degradation [17].  
• Aqueous Solubility  
Most of the drugs are weak acids or weak 
bases Drugs with low water solubility will be 
difficult to incorporate into sustained release 
mechanism. For a drug with high solubility 
and rapid dissolution rate, it is often quite 
difficult to retard its dissolution rate. A drug 
of high water solubility can dissolve in water 
or gastrointestinal fluid readily and tends to 
release its dosage form in a burst and thus is 
absorbed quickly leading to a sharp increase 
in the blood drug concentration compared to 
less soluble drug. It is often difficult to 
incorporate a highly water soluble drug in the 
dosage form and retard the drug release 
especially when the dose is high. The pH 
dependent solubility particularly in the 
physiological pH range would be another 
problem for Sustained release formulation 
because of the variation in the pH throughout 
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the gastrointestinal tract and variation in the 
dissolution rate. The biopharmaceutical 
classification system (BCS) allows estimation 
of likely contribution of three major factors 
solubility, dissolution and intestinal 
permeability which affect the oral absorption. 
Class III (High solubility- Low permeability) 
& Class IV (Low solubility- Low 
permeability) drugs are poor candidates for 
Sustained release dosage form compound with 
solubility < 0.1 mg/ml face significant 
solubilisation obstacles and often compounds 
with solubility 10 mg/ml present difficulties to 
solubilisation formulation. In general, highly 
soluble drugs are undesirable for formulation 
in to a Sustained release product [18]. 
 
B. Pharmacokinetic characteristics of drug in 
the design of SRDDS 
• Absorption rate  
A drug with slow absorption is a poor 
candidate for such dosage forms since 
continuous release will result in a pool of 
unabsorbed drug e.g iron. 
• Rate of metabolism 
Drug which is extensively metabolized is 
suitable for SRDDS as long as the rate of 
metabolism is not too rapid. 
• Elimination half life 
An ideal SRDDS is of the one from which rate 
of drug of absorption is equal to the rate of 
elimination. Smaller t1/2, larger the amount of 
drug to be incorporated in dosage form. Drugs 
with half life in the range 2 to 4 hours make 
good candidate for this system e.g 
propranolol. 
• Dosage form index 
It is define as the ratio of Css,max. to Css,min. since 
the goal of sustained-release formulation is to improve 
therapy by reducing the dosage form index while 
maintaining the plasma drug levels within the 
therapeutic window. 
C. Pharmacodynamic characteristics of drug in 
the design of SRDDS 
• Dose of drug 
Maximum dose strength for SRDDS is 
1gm. 
• Therapeutic range   
Drugs for SRDDS should have a wide 
therapeutic range [19]. 
• Therapeutic index 
Drugs with low therapeutic index are 
unsuitable for incorporation in Sustained 
release formulations. If the system fails in 
the body, dose dumping may occur, 
which leads to toxicity. 
• Plasma concentration response relationship  
Generally, plasma drug concentration is 
more responsible for pharmacological 
activity rather than dose. But the drug 
having pharmacological activity 
independent of plasma concentrations, are 
poor candidate for oral SR drug delivery 
system [20]. 
 
Drug selection for sustained release drug delivery 
system 
 
The scientific frame work required for successful 
development of oral drug delivery system consists of 
basic understanding of following aspects includes 
physiochemical, pharmacokinetics and 
pharmacodynamic characteristics of a drug, anatomical 
and physiomechanical characteristics of GI track, and 
physiomechanical characteristics of drug delivery 
mode of the dosage form to be designed. A number of 
physicochemical and pharmacokinetic parameters for 
the selecting of the drug to be formulated in sustained 
release dosage form which mostly includes the 
knowledge on the absorption mechanism of the drug 
form the GI tract [21]. Sustained (zero-order) drug 
release has been attempted to be achieved, by 
following classes of sustained drug delivery system 
[22]. 
 
Table 1.Physicochemical and pharmacokinetic parameters for drug selection 
Parameters  Criteria for drug selection  
Physicochemical parameters for drug selection  
Molecular size  < 1000 Daltons  
Aqueous Solubility  More than 0.1 mg/ml for pH 1 to pH 7.8  
Apparent partition coefficient  High  
Absorption mechanism  Diffusion  
General absorbability from all GI segments  Release Should not be influenced by pH and enzymes  
Pharmacokinetic parameters for drug selection  
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Elimination half-life (t1/2)  Between 2 to 8 hours  
Absolute bioavaliability  Should be 75% or more  
Absorption rate constant (Ka)  Must be higher than release rate  
Apparent volume of distribution (Vd)  Larger Vd and MEC, Larger will be the required dose  
Total clearance  Not depend on dose  
Elimination rate constant  Required for design  
Therapeutic concentration (Css)  The lower Css and smaller Vd, the loss among of drug 
required.  
Toxic concentration  Apart the value of MTC And MEC safer the dosage for  
 
Types of polymer 
Since the structural and physicochemical 
characteristics of the polymer are decisive in the drug 
release mechanism,some will be more suitable than 
others, depending on the aim pursued and the drug 
desired [23,24]. 
Hydrophilic polymers  
a) Cellulosic  
 
• Methylcellulose  
• Hydroxypropylmethylcellulose 
(Hypromellose, HPMC)  
• Hydroxypropylcellulose (HPC)  
• Hydroxyethylcellulose (HEC)  
• Ethylhydroxyethylcellulose (E-HEC)  
• Sodium carboxymethylcellulose (Na-CMC)  
b)Non-cellulosic  
• Sodium alginate  
• Xanthan gum  
• Carrageenan  
• Chitosan  
• Guar gum  
• Pectin  
• Cross-linked high amylose starch  
• Polyethylene oxide  
• Homopolymers and copolymers of acrylic 
acid  
 
Hydrophobic polymers  
• Ethylcellulose  
• Hypromellose acetate succinate  
• Cellulose acetate  
• Cellulose acetate propionate  
• Methacrylic acid copolymers  
• Polyvinyl acetate  
MODELLING AND COMPARISON OF 
DISSOLUTION PROFILE 
Several theories and kinetic models were described the 
drug release characteristics of immediate release and 
modified release dosage forms, by using dissolution 
data and quantitative interpretation of values obtained 
in dissolution assay if facilitated by the usage of the 
generic equation dosage form that mathematically 
translates the dissolution curve in function of some 
parameters related with pharmaceutical dosage form. In 
the present work, some analytical models were used to 
study the mechanism of drug release of extended 
release by following models 
Zero order 
It is ideal method of drug release in order to achieve a 
pharmacological prolonged action.Drug dissolution 
from pharmaceutical dosage form that doesn’t 
disaggregates and release the 
drug slowly can be represented by the following 
equation 
                                      Q0 = Q0 + K0 t 
Where 
Qt =amount of drug released in time t 
Q0= initial amount of drug in solution 
K0 =zero order release constant 
 
First Order Release Kinetics 
Wagner assuming that the exposed surface area of a 
tablet decreased exponentially with time during 
dissolution process suggested that drug release from 
most of the slow release tablets could be described 
adequately by apparent first-order kinetics. The 
equation that describes first order kinetics is 
                                                            In (1-Q) = - K1t 
Where, Q is the fraction of drug released at time t and 
k1 is the first order release rate constant. Thus, a plot of 
the logarithm of the fraction of drug remained against 
time will be linear if the release obeys first order 
release kinetics. 
 
Higuchi equation  
 
It defines a linear dependence of the active fraction 
released per unit of surface (Q) on the square root of 
time. 
Q=K2t½ 
Where, K2 is the release rate constant. A plot of the 
fraction of drug released against square root of time 
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will be linear if the release obeys Higuchi equation. 
This equation describes drug release as a diffusion 
process based on the Fick’s law, square root time 
dependant.  
Power Law 
In order to define a model, which would represent a 
better fit for the formulation, dissolution data was 
further analyzed by Peppa’s and Korsemeyer equation 
(Power Law). 
 
         Mt/Mα=K tn 
Where, Mt is the amount of drug released at time t and 
Mα is the amount released at time α, thus the Mt/Mα is 
the fraction of drug released at time t, k is the kinetic 
constant and n is the diffusion exponent. To 
characterize the mechanism for both solvent 
penetration and drug release n can be used as 
abstracted in Table. A plot between log of Mt/Mα 
against log of time will be linear if the release obeys 
Peppa’s and Korsemeyer equation and the slope of this 
plot represents “n” value (diffusion coefficient) which 
describes mechanism of diffusion [25]. 
Hixson-Crowell model 
Hixson-Crowell (1931) recognising that particle 
regular area is proportional to the cubic root of its 
volume derived an equation that can be described in the 
following manner 
         W01/3 – W01/3 =Ks t  
Where 
W0 is the initial amount of drug in the 
pharmaceutical dosage form 
Wt is the remaining amount of drug 
pharmaceutical dosage form at time t 
Ks is the constant incorporating the 
surface volume relation [26]. 
Characterization of sustained release tablets 
 
Before marketing a sustained release product, it can be 
evaluated and characterized by using different 
parameters including in vitro, ex vivo and by in vivo 
(Clinical) procedures, and it is must to assure the 
strength, safety, stability and reliability of a product. A 
number of techniques have been used to characterize 
SRDDS and determine the various feasibility or 
flexibility of their formulation process. Various authors 
have discussed the evaluating parameters and 
procedures for sustained release formulations.  
• Pre and post compression parameters : 
Most widely used parameters are bulk density, 
tapped density, compressibility index, hausner 
ratio, total porosity, flow rate, angle of repose, 
hardness, friability, weight variation test and 
uniformity of drug content etc.  
• In–Vitro Methods  
The various types of methods used are beaker, 
rotating disc, rotating bottle, rotating basket, 
stationary basket, oscillating tube, dialysis and 
USP dissolution method.  
• In–Vivo Methods  
 Once the satisfactory in-vitro profile is 
achieved, it becomes necessary to conduct in-
vivo evaluation and establish in-vitro in-vivo 
correlation. The various in-vivo evaluation 
methods are clinical response, blood level 
data, urinary excretion studies, nutritional 
studies, toxicity studies and radioactive tracer 
techniques.  
• Stability Studies  
• In vitro- In vivo Correlation (IVIVC)  
• Bioavailability Testing  
• In vitro drug release characterization models: 
Mathematical Models .The various types of 
modals used are zero order release kinetics, 
first order release kinetics, Higuchi model, 
Hixson-Crowell cube root law and 
Korsmeyer-Peppas model [27].   
Conclusion 
 
There are several reasons for attractiveness of sustained 
release drug delivery system, provides increased 
bioavailability of drug product, reduction in the 
frequency of administration to prolong duration of 
effective blood levels, reduces the fluctuation of peak 
trough concentration and side effects and possibly 
improves the specific distribution of the drug. From the 
above discussion, we can concluded that development 
of SRDDS depend upon various factors such as 
Biopharmaceutics, Pharmacokinetic and 
Pharmacodynamic characteristics of drug. Sustained 
release formulations are a promising way to improve 
the patient compliance by reducing dosing interval and 
minimizing adverse effect. 
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